Phase 2 Trial of BCNU [carmustine] Plus O6-Benzylguanine (NSC 637037) in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme.

Trial Profile

Phase 2 Trial of BCNU [carmustine] Plus O6-Benzylguanine (NSC 637037) in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2013

At a glance

  • Drugs Benzylguanine (Primary) ; Carmustine (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top